Adarsh Shankar, Meenu Jain, Mei Jing Lim, Kartik Angara, Peng Zeng, Syed A Arbab, Asm Iskander, Roxan Ara, Ali S Arbab, Bhagelu R Achyut
OBJECTIVE: Anti-angiogenic therapies (AATs), targeting VEGF-VEGFR pathways, are being used as an adjuvant to normalize glioblastoma (GBM) vasculature. Unexpectedly, clinical trials have witnessed transient therapeutic effect followed by aggressive tumor recurrence. In pre-clinical studies, targeting VEGFR2 with vatalanib, increased GBM growth under hypoxic microenvironment. There is limited understanding of these unanticipated results. Here, we investigated tumor cell associated phenotypes in response to VEGFR2 blockade...
2016: Journal of Cancer Science & Therapy